Escutrix
Escutrix Uses, Dosage, Side Effects, Food Interaction and all others data.
Escutrix, also known as diferuloylmethane, is an active component in the golden spice turmeric (Curcuma longa) and in Curcuma xanthorrhiza oil. It is a highly pleiotropic molecule that exhibits antibacterial, anti-inflammatory, hypoglycemic, antioxidant, wound-healing, and antimicrobial activities . Due to these properties, curcumin has been investigated for the treatment and supportive care of clinical conditions including proteinuria, breast cancer, multiple myeloma, depression, and Non Small Cell Lung Cancer (NSCLC). Despite proven efficacy against numerous experimental models, poor bioavailability due to poor absorption, rapid metabolism, and rapid systemic elimination have been shown to limit the therapeutic efficacy of curcumin . Escutrix is under investigation for the treatment and supportive care of various clinical conditions including mucositis, rectal cancer, prostate cancer, chronic schizophrenia, and Mild Cognitive Impairment (MCI) .
Intravenous application of 25 mg/kg bw curcumin to rats resulted in an increase in bile flow by 80 and 120% . In the rat model of inflammation, curcumin was shown to inhibit edema formation. In nude mouse that had been injected subcutaneously with prostate cancer cells, administration of curcumin caused a marked decrease in the extent of cell proliferation, a significant increase of apoptosis and micro-vessel density . Escutrix may exert choleretic effects by increasing biliary excretion of bile salts, cholesterol, and bilirubin, as well as increasing bile solubility . Escutrix inhibited arachidonic acid-induced platelet aggregation in vitro .
| Trade Name | Escutrix |
| Generic | Curcumin |
| Weight | 500mg |
| Type | Capsule |
| Formula | C21H20O6 |
| Weight | Average: 368.3799 Monoisotopic: 368.125988372 |
| Protein binding | No pharmacokinetic data available. |
| Groups | Approved, Investigational |
| Therapeutic Class | |
| Manufacturer | Esmatrix Life Sciences Pvt Ltd |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
No approved therapeutic indications.
How Escutrix works
Escutrix acts as a scavenger of oxygen species, such as hydroxyl radical, superoxide anion, and singlet oxygen and inhibit lipid peroxidation as well as peroxide-induced DNA damage . Escutrix mediates potent anti-inflammatory agent and anti-carcinogenic actions via modulating various signalling molecules. It suppresses a number of key elements in cellular signal transduction pathways pertinent to growth, differentiation, and malignant transformation; it was demonstrated in vitro that curcumin inhibits protein kinases, c-Jun/AP-1 activation, prostaglandin biosynthesis, and the activity and expression of the enzyme cyclooxygenase (COX)-2 .
Toxicity
In an acute oral toxicity study in mouse, LD50 was >2000 mg/kg . Single oral doses of curcumin at 1-5 g/kg bw induced no toxic effects in rats . There has been no cases of overdose reported .
Volume of Distribution
Following oral administration of radio-labelled curcumin to rats, radioactivity was detected in the liver and kidneys .
Elimination Route
Escutrix displays poor absorption into the gastrointestinal tract. In a rat study, oral administration of a single dose of 2 g of curcumin resulted in a plasma concentration of less than 5 μg/mL, indicating poor absorption from the gut .
Half Life
No pharmacokinetic data available.
Clearance
No pharmacokinetic data available.
Elimination Route
Following oral administration of curcumin to rats at a dose of 1 g/kg bw, about 75% of dose was excreted in the faeces and only traces of the compound was detected in the urine . When a single 400 mg dose of curcumin was administered orally to rats, about 60% was absorbed and 40% was excreted unchanged in the faeces over an period of 5 days . Intraperitoneal administration resulted in fecal excretion of 73% and biliary excretion of 11% .
Innovators Monograph
You find simplified version here Escutrix
